CHICAGO, May 6, 2011 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that its exclusive distributorin Brazil, Semina Industria e Comercio (Semina), was successful in a public tender to supply the Brazilian Ministry of Health (MOH) with up to 20 million FC2 Female Condoms. The contract is valid through March
O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that the contract reflects Brazil's and the MOH's leadership in providing women with options to control their health and in further enhancing the national HIV/AIDS prevention program.
FHCO and Semina have agreed to install a local FC2 production facility in Brazil if nationwide consumption continues to grow significantly, reaching an average of 20 million units annually.
Parrish reaffirmed the statement in the Company's February 4, 2011 earnings release that it may experience significant quarter to quarter variations in results due to the timing of substantial orders and that it expected modest results for the first half of fiscal 2011 and strong results for the second half of the fiscal year.
About The Female Health Company
The Female Health Company (FHC), based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 100 other countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, China, Spain, Mexico, Greece and Turkey and are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
About Semina Industria e Comercio
Semina Industria e Comercio Ltda, based in Sao Paulo, Brazil, is FHC's exclusive distributor of FC2 female condoms in Brazil. Semina also manufactures silicon diaphragms for Johnson & Johnson worldwide, certified by FDA, CE and ISO 13485. The Company is also a leading developer and distributor of educational materials focused on reproductive health and family planning. Semina subscribes to the highest international standards of quality and holds certifications of Good Manufacturing Practices and Distribution and its products are duly registered with ANVISA (Brazilian Regulatory Sanitary Agency).
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release relate to the continuation of cash dividends in future periods. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2010. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company
Subscribe to our Free Newsletters!
The Hib vaccine protects children against infections like meningitis and pneumonia that are caused ...
Dysthymia or persistent depressive disorder (PDD) is a chronic low mood and self-esteem affecting ...
Vitamin A is an extremely vital vitamin needed for the eyes, skin, hair, immunity and during ...View All